Bio-Rad

Bio-Rad also disclosed during an earnings call that it acquired an undisclosed company that will expand its genomic reagents product portfolio.

The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.

The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.

The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.

The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.

The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad. 

The contract covers Bio-Rad's iQ-Check RT-PCR pathogen detection test kits, which cover pathogens including Salmonella spp. and Listeria monocytogenes.